Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 11/20 | 0.66 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.48 |
| ▸ | RAF1 | P04049 | 2/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 4/20 | 0.40 |
| ▸ | DRD3 | P35462 | 4/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29316555 | 0.86 | AR (0.57) | ARHTR2ADRD3 | |
| SCHEMBL29316564 | 0.86 | AR (0.56) | AR | |
| SCHEMBL24632253 | 0.84 | USP30 (0.52) | ARUSP30RAF1BRAFSMYD3 | |
| SCHEMBL29665883 | 0.84 | USP30 (0.52) | ARUSP30RAF1BRAFSMYD3 | |
| SCHEMBL29316534 | 0.82 | AR (0.53) | AR | |
| SCHEMBL29316248 | 0.79 | USP30 (0.50) | ARUSP30SMYD3HTR2ADRD3 | |
| SCHEMBL24031880 | 0.79 | AR (0.82) | ARUSP30SMYD3 | |
| SCHEMBL29316526 | 0.78 | AR (0.49) | AR | |
| SCHEMBL27027445 | 0.78 | AR (0.49) | AR | |
| SCHEMBL24031878 | 0.77 | AR (0.80) | ARUSP30SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239749-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239749-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | AR 658/4885USP30 2321/4885RAF1 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.